Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(n/a)
# 2,701
Out of 4,827 analysts
107
Total ratings
10%
Success rate
-29.9%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: In-Line | $8 → $7 | $7.08 | -1.13% | 3 | May 1, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $165 → $200 | $180.93 | +10.54% | 13 | May 1, 2025 | |
| DGX Quest Diagnostics | Maintains: In-Line | $175 → $180 | $175.90 | +2.33% | 3 | Apr 23, 2025 | |
| HCAT Health Catalyst | Downgrades: In-Line | $6 → $4 | $4.18 | -4.31% | 6 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $20 → $15 | $5.95 | +152.10% | 7 | Mar 4, 2025 | |
| MCK McKesson | Maintains: Outperform | $650 → $675 | $690.25 | -2.21% | 5 | Feb 6, 2025 | |
| CVS CVS Health | Maintains: Outperform | $60 → $65 | $67.85 | -4.20% | 6 | Jan 27, 2025 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $11.16 | +7.53% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $248.76 | +6.53% | 4 | Jan 7, 2025 | |
| XRAY DENTSPLY SIRONA | Downgrades: In-Line | $20 | $15.91 | +25.71% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $140 | $147.27 | -4.94% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $40.49 | -11.09% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $265 | $153.29 | +72.87% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $59.35 | -24.18% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $3.22 | +24.22% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $17.77 | +29.43% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $25.07 | -20.22% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $8.37 | +213.62% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $5.37 | +179.33% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.73 | +302.93% | 2 | Jan 4, 2022 |
Teladoc Health
May 1, 2025
Maintains: In-Line
Price Target: $8 → $7
Current: $7.08
Upside: -1.13%
Align Technology
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $180.93
Upside: +10.54%
Quest Diagnostics
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $175.90
Upside: +2.33%
Health Catalyst
Apr 9, 2025
Downgrades: In-Line
Price Target: $6 → $4
Current: $4.18
Upside: -4.31%
Fortrea Holdings
Mar 4, 2025
Maintains: In-Line
Price Target: $20 → $15
Current: $5.95
Upside: +152.10%
McKesson
Feb 6, 2025
Maintains: Outperform
Price Target: $650 → $675
Current: $690.25
Upside: -2.21%
CVS Health
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $67.85
Upside: -4.20%
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.16
Upside: +7.53%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $248.76
Upside: +6.53%
DENTSPLY SIRONA
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $15.91
Upside: +25.71%
Jan 7, 2025
Upgrades: Outperform
Price Target: $140
Current: $147.27
Upside: -4.94%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $40.49
Upside: -11.09%
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $153.29
Upside: +72.87%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $59.35
Upside: -24.18%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $3.22
Upside: +24.22%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $17.77
Upside: +29.43%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $25.07
Upside: -20.22%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $8.37
Upside: +213.62%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $5.37
Upside: +179.33%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.73
Upside: +302.93%